PDAC (Pancreatic ductal adenocarcinoma) due to the lack of early detection and the limited response to designed treatments, is considered to have a terrible prognosis. PDC is highly aggressive with lethal malignancy. PDAC is the most common type of pancreatic neoplasm, and accounts for more than 90% of pancreatic cancer cases . PDAC has an average 5-year survival rate of less than 10% . The need for new treatments for pancreatic cancer is pertinent, as many of the on-market compounds are limited for the direct treatment of pancreatic cancer. The poor genomic and proteomic analysis of various tumors fails to distinguish the proper target and treatment plan. Aside from poor prognosis, TME (tumor microenvironment) is characterized by dense desmoplasia and extensive immunosuppression. Extensive desmoplasia results in various cell infiltration, vascularization, and hypoxia, preventing drugs to target such areas specifically . PDAC target through this experiment, is through GPCR ligand targeting, as the membrane protein is present it also accounts for 20% of all cancers that contain a mutated GPCR or g-alpha subunits . Targeting this receptor using cannabinoids might prove to be a possible target of choice as GPCRs mediate a broad range of autocrine and paracrine responses in cancer cells. They bind to a diverse group of ligands, including small peptides, lipids, and proteins (e.g., chemokines) . The density of GPCRs on the cell surface is typically 10 3 -10 4 receptors/cell, which should be adequate to ensure ample uptake of the targeted drug cargo .